Small Animal Internal Medicine

Research Abstract

GI16 - Longitudinal Characterization of the Fecal Microbiome in Dogs with Idiopathic Inflammatory Bowel Disease

Thursday, June 14
3:15 PM - 3:30 PM
Location: WSCC 618/619

Idiopathic inflammatory bowel disease (IBD) is characterized by intestinal mucosal inflammation  and is  associated with alterations in the gut microbiome or intestinal dysbiosis. Treatment is directed at the pathophysiologic mechanisms and often includes dietary modification, antibiotics, and/or immunosuppressants. Treatment responses are often suboptimal, and relapses are common, making management of IBD a challenge. Intestinal dysbiosis is present at the time of diagnosis in dogs with IBD, however changes in the microbiome over time in dogs undergoing standard immunosuppresssive therapy have not been well characterized. The purpose of this study was to evaluate longitudinal changes of the intestinal microbiome in dogs with IBD  being treated with prednisone.

Thirteen dogs diagnosed with idiopathic IBD, that previously failed to respond to treatment with elimination diets and metronidazole, were enrolled. Stool samples were collected from all dogs before initiating therapy with prednisone, after 3 and 8 weeks, and more than one year after beginning treatment. Thirteen healthy dogs were enrolled in the study as a control group. Stool samples were kept frozen at -80oC until DNA extraction. The microbiota was characterized using Illumina sequencing of 16S rRNA genes. Data were analyzed using Quantitative Insights Into Microbial Ecology (QIIME). Beta diversity was evaluated with the phylogeny based unweighted UniFrac distance metric, and statistics were performed with the Analysis of Similarities (ANOSIM).

In the IBD group, clinical disease severity (CIBDAI) at baseline was scored as moderate to severe. All dogs achieved partial or complete remission of clinical signs by 3 or 8 weeks of treatment, and CIBDAI scores were significantly reduced after 8 weeks of treatment (p < 0.001). At baseline, dogs with IBD showed differences in microbial composition when compared to healthy dogs, as unweighted UniFrac distances demonstrated significantly different beta diversity between groups (p=0.001, R=0.462). Differences in the IBD group included increased Firmicutes (p < 0.001) and Actinobacteria (p=0.027), and reduced Bacteroidetes (p < 0.001), Fusobacteria (p < 0.001) and Proteobacteria (p=0.006). Within the IBD group, beta diversity was still significantly changed at 8 weeks (p < 0.001) compared to healthy controls. At the 1 year follow up, diversity metrics placed the microbiome of treated dogs closer to that of healthy dogs, but they were still significantly different  from those of healthy controls (p=0.003, R=0.258).

Our results suggest that, while treatment can be effective in improving clinical signs, the dysbiosis associated with IBD is still present after more than one year after the initiation of immunosuppressive therapy, even when dogs were clinically well controlled.

Rachel Pilla, DVM, PhD

Post Doctoral Research Associate
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, TX.


Send Email for Rachel Pilla


GI16 - Longitudinal Characterization of the Fecal Microbiome in Dogs with Idiopathic Inflammatory Bowel Disease


Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Longitudinal Characterization of the Fecal Microbiome in Dogs with Idiopathic Inflammatory Bowel Disease